Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imatinib mesylate + panitumumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Imatinib mesylate + panitumumab is a combination of two targeted cancer therapies. Imatinib is a small molecule tyrosine kinase inhibitor that blocks the activity of BCR-ABL, c-Kit, and platelet-derived growth factor receptor (PDGFR), thereby inhibiting cell proliferation and inducing apoptosis in certain cancers such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST)[2][6]. Panitumumab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), blocking its activation and downstream signaling pathways involved in tumor cell growth. It is indicated for metastatic colorectal cancer with wild-type RAS[4][8]. The combination has been studied in early-phase clinical trials for metastatic colorectal cancer to explore potential synergistic effects by targeting multiple signaling pathways[5].
- Other names
- imatinibpanitumumab
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on imatinib mesylate + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imatinib mesylate + panitumumab.